Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Glofit-Pola demonstrated high efficacy and durable responses, with manageable safety, in heavily pretreated patients with R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy failure.
Authors
- Alan P Skarbnik (ORCID: https://orcid.org/0000-0002-1276-7546)
- Giuseppe Gritti (ORCID: https://orcid.org/0000-0002-6789-5123)
- Abraham Avigdor (ORCID: https://orcid.org/0000-0002-7448-869X)
- Maneesh Tandon
- Gila Sellam (ORCID: https://orcid.org/0000-0002-7342-7668)
- Thomas Stauffer Larsen (ORCID: https://orcid.org/0000-0002-8418-6708)
- Antonio Pinto (ORCID: https://orcid.org/0000-0002-9425-9026)
- Paolo Corradini (ORCID: https://orcid.org/0000-0002-9186-1353)
- Francesc Bosch (ORCID: https://orcid.org/0000-0001-9241-2886)
- Antonio Rueda‐Domínguez (ORCID: https://orcid.org/0000-0001-5890-0149)
- María José Terol (ORCID: https://orcid.org/0000-0002-9467-932X)
- Martin Hutchings (ORCID: https://orcid.org/0000-0003-3873-1741)
- Wilfred Leung (ORCID: https://orcid.org/0000-0002-0346-2214)
- James Relf
- Anna Sureda (ORCID: https://orcid.org/0000-0002-1238-6970)
- Raúl Córdoba (ORCID: https://orcid.org/0000-0002-7654-8836)
- Alessia Bottos (ORCID: https://orcid.org/0000-0001-6311-2833)
- Pier Luigi Zinzani (ORCID: https://orcid.org/0000-0002-2112-2651)
- Donghang Li (ORCID: https://orcid.org/0009-0001-2961-7202)
- Judit Meszaros Jørgensen (ORCID: https://orcid.org/0000-0001-9784-2703)
Institutions
- Roche (Switzerland) (CH)
- University of Copenhagen (DK)
- Universitat de València (ES)
- Sheba Medical Center (IL)
- Odense University Hospital (DK)
- Novant Health (US)
- Aarhus University Hospital (DK)
- Rigshospitalet (DK)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Ospedale Papa Giovanni XXIII (IT)
- Roche (United Kingdom) (GB)
- Istituto di Ematologia di Bologna (IT)
- Azienda USL di Bologna (IT)
- Roche (China) (CN)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- Vall d'Hebron Institute of Oncology (ES)
- University of Bologna (IT)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1200/jco-25-00992
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- F. Hoffmann-La Roche